Business
Axsome Therapeutics to Present New Sunosi® Data at SLEEP 2023
Cognitive improvement with Sunosi sustained over eight hours in patients with excessive daytime sleepiness due to obstructive sleep apnea NEW YORK, June 01,
About this update from Axsome Therapeutics, Inc.
[{"type":"text","content":"Cognitive improvement with Sunosi sustained over eight hours in patients with excessive daytime sleepiness due to obstructive sleep apnea\nNEW YORK, June 01, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced presentations on Sunosi® (solriamfetol) at SLEEP 2023, the annual meeting of the American Academy of Sleep Medicine and the Sleep Research Society, being held in Indianapolis, Ind., from June 3-7, 2023. The presentations include new data from the SHARP (Solriamfetol’s Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-controlled) study in patients with excessive daytime sleepiness (EDS) associated with obstructive sleep apnea (OSA), demonstrating sustained improvement with Sunosi on measures of cognition across 8-hours with once daily dosing. Additional new data and analyses include real-world data from OSA patients taking Sunosi as part of the SURWEY study in Germany, healthcare resource use in OSA patients with residual EDS, and effect sizes and numbers needed to treat analyses. “Cognitive impairment is a substantial burden to many patients with EDS and OSA. The results of the SHARP study are particularly exciting because they demonstrate a robust improvement in cognitive function that was sustained throughout the day,” said Hans Van Dongen, PhD, Professor at Washington State University and first author of the SHARP study abstract. “Not only was there an objective change in cognitive performance, but patients also reported a measurable improvement in their symptoms, suggesting solriamfetol can be an effective option for the treatment of patients with EDS due to OSA.” Details for the upcoming SLEEP Meeting presentations are as follows: Title: Solriamfetol Demonstrates Durable Cognitive Improvement in Adults with Obstructive Sleep Apnea and Excessive Daytime Sleepiness Poster Session: P-29 Lead Author: Hans Van Dongen, PhD, Professor at Washington State University Date/Time: June 6, 2023, from 5:00 – 6:00 p.m. Eastern TimePoster Board Number: 168 Title: SURWEY Study of Solriamfetol: Initiation, Titration, Safety, Efficacy, and Follow-Up Experience for Patients with OSA in German Poster Session: P-29 Lead Author: Yaroslav Winter, MD, Main...